<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308839</url>
  </required_header>
  <id_info>
    <org_study_id>FPR12-02</org_study_id>
    <nct_id>NCT02308839</nct_id>
  </id_info>
  <brief_title>GORE® EXCLUDER® Endoprosthesis French Mandatory Registry</brief_title>
  <official_title>Study of the GORE® EXCLUDER® Endoprosthesis in the Treatment of Infra-renal Abdominal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a French Registry mandated by the French National Health Authority assessing
      long-term (5-years) safety of the GORE® Excluder® Endoprosthesis in the treatment of
      infra-renal Abdominal Aortic Aneurysms (AAA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of abdominal aortic endoprostheses makes the treatment of infra-renal abdominal
      aortic aneurysms possible, with implantation via the femoral artery, thus avoiding a very
      invasive surgical procedure. The French National Authority for Health requires a 5-year
      follow-up as part of the renewal for reimbursement for these endoprostheses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">October 5, 2018</completion_date>
  <primary_completion_date type="Actual">September 26, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Percentage of Participants Survived at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Kaplan-Meier estimate of participant survival at 5 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Endoleak at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Kaplan-Meier estimate of participant freedom from endoleak (Type I, II and III) at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Migration at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Kaplan-Meier estimate of participant freedom from migration at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Aneurysm Diameter Growth at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Kaplan-Meier estimate of participant freedom from aneurysm diameter growth at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Aneurysm Related Mortality at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Kaplan-Meier estimate of participant freedom from aneurysm related mortality at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Endovascular or Surgical Re-intervention at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Kaplan-Meier estimate of participant freedom from endovascular or surgical re-intervention at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Surgical Conversion at Procedure</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Participant freedom from surgical conversion at procedure</description>
  </secondary_outcome>
  <enrollment type="Actual">181</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE® EXCLUDER® Endoprosthesis</intervention_name>
    <description>Endovascular therapy to treat abdominal aortic aneurysms</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring treatemtn with an endoprosthesis for the treatment of an unruptured
        infra-renal aortic abdominal aneurysm.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patients requiring abdominal aortic stenting for the treatment of an unruptured
             infra-renal aortic abdominal aneurysm.

        Exclusion Criteria:

          -  Patients whose clinical follow-up is not possible, i.eg, patient who cannot return for
             control visits (e.g. patients living abroad).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Steinmetz, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire du Bocage</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <results_first_submitted>April 14, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2020</results_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aneurysm</keyword>
  <keyword>Aorta</keyword>
  <keyword>Abdominal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 29, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02308839/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02308839/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
          <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
          <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.4" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Survived at 5 Years</title>
        <description>Kaplan-Meier estimate of participant survival at 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
            <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Survived at 5 Years</title>
          <description>Kaplan-Meier estimate of participant survival at 5 years</description>
          <units>Percentage of participants alive</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free From Endoleak at 5 Years</title>
        <description>Kaplan-Meier estimate of participant freedom from endoleak (Type I, II and III) at 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
            <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free From Endoleak at 5 Years</title>
          <description>Kaplan-Meier estimate of participant freedom from endoleak (Type I, II and III) at 5 years</description>
          <units>Percentage free from endoleak</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free From Migration at 5 Years</title>
        <description>Kaplan-Meier estimate of participant freedom from migration at 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
            <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free From Migration at 5 Years</title>
          <description>Kaplan-Meier estimate of participant freedom from migration at 5 years</description>
          <units>Percentage free from migration</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free From Aneurysm Diameter Growth at 5 Years</title>
        <description>Kaplan-Meier estimate of participant freedom from aneurysm diameter growth at 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
            <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free From Aneurysm Diameter Growth at 5 Years</title>
          <description>Kaplan-Meier estimate of participant freedom from aneurysm diameter growth at 5 years</description>
          <units>Percentage free from aneurysm growth</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free From Aneurysm Related Mortality at 5 Years</title>
        <description>Kaplan-Meier estimate of participant freedom from aneurysm related mortality at 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
            <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free From Aneurysm Related Mortality at 5 Years</title>
          <description>Kaplan-Meier estimate of participant freedom from aneurysm related mortality at 5 years</description>
          <units>Percentage free from mortality</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free From Endovascular or Surgical Re-intervention at 5 Years</title>
        <description>Kaplan-Meier estimate of participant freedom from endovascular or surgical re-intervention at 5 years</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
            <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free From Endovascular or Surgical Re-intervention at 5 Years</title>
          <description>Kaplan-Meier estimate of participant freedom from endovascular or surgical re-intervention at 5 years</description>
          <units>Percentage free from re-intervention</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free From Surgical Conversion at Procedure</title>
        <description>Participant freedom from surgical conversion at procedure</description>
        <time_frame>Index Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
            <description>GORE® EXCLUDER® AAA Endoprosthesis</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free From Surgical Conversion at Procedure</title>
          <description>Participant freedom from surgical conversion at procedure</description>
          <units>Percentage free from conversion</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five year follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GORE® EXCLUDER® AAA Endoprosthesis</title>
          <description>GORE® EXCLUDER® AAA Endoprosthesis Registry conducted for reimbursement in France, and no MedDRA coding was required.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device Related</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Procedure Related</sub_title>
                <description>Procedure Related but not Device Related</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aneurysm Related</sub_title>
                <description>Aneurysm Related but not Device Related or Procedure Related</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device Related</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Procedure Related</sub_title>
                <description>Procedure Related but not Device Related</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Aneurysm Related</sub_title>
                <description>Aneurysm Related but not Device Related or Procedure Related</description>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="181"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="181"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Abe Letter</name_or_title>
      <organization>W.L. Gore &amp; Associates</organization>
      <phone>928-864-3113</phone>
      <email>aletter@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

